For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
27
references
 Top references
cited by
154
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      121
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment measures cannot identify those at risk. A predictive model for chemotherapy toxicity was developed (N = 500) that consisted of geriatric assessment questions and other clinical variables. This study aims to externally validate this model in an independent cohort (N = 250).

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          The meaning and use of the area under a receiver operating characteristic (ROC) curve.

          J A Hanley, B J McNeil, Marnix van Holsbeeck (1982)
          A representation and interpretation of the area under a receiver operating characteristic (ROC) curve obtained by the "rating" method, or by mathematical predictions based on patient characteristics, is presented. It is shown that in such a setting the area represents the probability that a randomly chosen diseased subject is (correctly) rated or ranked with greater suspicion than a randomly chosen non-diseased subject. Moreover, this probability of a correct ranking is the same quantity that is estimated by the already well-studied nonparametric Wilcoxon statistic. These two relationships are exploited to (a) provide rapid closed-form expressions for the approximate magnitude of the sampling variability, i.e., standard error that one uses to accompany the area under a smoothed ROC curve, (b) guide in determining the size of the sample required to provide a sufficiently reliable estimate of this area, and (c) determine how large sample sizes should be to ensure that one can statistically detect differences in the accuracy of diagnostic techniques.
          Article 0 comments Cited 3964 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach

            David DeLong, Elizabeth Delong, Daniel L Clarke-Pearson (1988)
            Article 0 comments Cited 2974 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer statistics, 2015.

              Rebecca Siegel, Kimberly D Miller, Ahmedin Jemal (2015)
              Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. A total of 1,658,370 new cancer cases and 589,430 cancer deaths are projected to occur in the United States in 2015. During the most recent 5 years for which there are data (2007-2011), delay-adjusted cancer incidence rates (13 oldest SEER registries) declined by 1.8% per year in men and were stable in women, while cancer death rates nationwide decreased by 1.8% per year in men and by 1.4% per year in women. The overall cancer death rate decreased from 215.1 (per 100,000 population) in 1991 to 168.7 in 2011, a total relative decline of 22%. However, the magnitude of the decline varied by state, and was generally lowest in the South (∼15%) and highest in the Northeast (≥20%). For example, there were declines of 25% to 30% in Maryland, New Jersey, Massachusetts, New York, and Delaware, which collectively averted 29,000 cancer deaths in 2011 as a result of this progress. Further gains can be accelerated by applying existing cancer control knowledge across all segments of the population. © 2015 American Cancer Society.
              Article 0 comments Cited 990 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): J. Clin. Oncol.
                Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
                ISSN (Electronic): 1527-7755
                ISSN (Print): 0732-183X
                Publication date (Electronic): Jul 10 2016
                Volume: 34
                Issue: 20
                Affiliations
                [1 ] Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands. ahurria@coh.org.
                [2 ] Arti Hurria, Tao Feng, David Smith, Can-Lan Sun, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, and Chie Akiba, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA; Supriya Mohile, University of Rochester Medical Center, Rochester; Ajeet Gajra, Upstate Medical University and Syracuse VA Medical Center, Syracuse; William P. Tew, Memorial Sloan Kettering Cancer Center, New York, NY; Heidi Klepin, Wake Forest University School of Medicine, Winston Salem; Hyman Muss, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill; Harvey Jay Cohen, Duke University, Durham, NC; Andrew Chapman, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; and Nienke De Glas, Leiden University Medical Centre, Leiden, the Netherlands.
                Article
                Publisher Item ID: JCO.2015.65.4327
                DOI: 10.1200/JCO.2015.65.4327
                PubMed ID: 27185838
                SO-VID: 7f0fc934-2012-4444-bcad-2e7236c3479e
                Copyright © © 2016 by American Society of Clinical Oncology.
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content121

                See all similar

                Cited by154

                See all cited by

                Most referenced authors783

                See all reference authors